Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
01. Dezember 2021 15:25 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain...
Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018
28. August 2018 13:31 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split
22. März 2018 11:35 ET
|
Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that...
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
01. März 2018 16:20 ET
|
Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017
29. November 2017 09:30 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress
02. November 2017 16:52 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
31. Oktober 2017 06:45 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
03. Oktober 2017 12:00 ET
|
Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...